Medtech grants in the Netherlands

Funds R&D on rapid tests that detect chemical and biological agents, including biotoxins.

Funds R&D on vaccines and drugs that protect against chemical, biological, radiological and nuclear threats.

Funds R&D on reusable respiratory protective equipment and protection suits against chemical, biological, radiological and nuclear threats.

Closed

Funds research that measures wasteful or low-value healthcare practices and pilots ways to cut them, freeing up resources for care that actually helps patients.

Closed

Funds medical, technological and care research that prevents, reverses or reduces the severity of intellectual disability and supports the families who care for those affected.

Closed

Funds clinical trials of new drug-based therapies, paired with a complementary approach like neurostimulation or digital monitoring, for conditions such as depression, schizophrenia, PTSD and autism spectrum disorder.

Closed

Funds clinical trials that validate affordable, minimally-invasive surgery-centred treatments for cancer patients with locally advanced or metastatic disease.

Funds one project to standardise beta-cell manufacturing, immune-tolerance strategies and clinical criteria that speed up cell therapy for type 1 diabetes.

Closed

Funds multi-country clinical studies that generate the safety and performance data device makers need for CE marking of orphan or breakthrough medical devices.

Closed

Funds development of lab-grown human tissue models, organ-on-chip systems and AI-driven simulations that can replace animal testing in drug and medical device development.

Funds late-stage development of new diagnostic tests for vector-borne diseases such as those spread by mosquitoes and ticks.

Closed

Pays three European projects EUR 7.5 million each to develop advanced-materials sensors, from multifunctional surfaces to miniaturised wearable devices, with a guaranteed award in each of two research areas.

Closed

Funds research linking diet and nutrients to mental health, aiming at evidence and guidance for policymakers and health professionals.

Closed

Funds industry-academia consortia that refine and scale up the manufacturing process for one class of cell or gene therapy, from quality control through to deployment.

Funds one project to map, replace, reduce and safely dispose of PFAS chemicals used in medicines, vaccines, devices and diagnostics.

Funds EU-wide work to pilot, roll out and evaluate lung cancer screening programmes, including AI-based detection tools.

Funds EU-wide piloting and rollout of prostate cancer screening programmes, including cross-border AI research on screening data.

Closed

Funds research proving the causal link between pollution exposure and neurological, neurodegenerative or neurodevelopmental disease, using biomarkers, imaging and long-term cohort data.

Closed

Funds research into the prevention, diagnosis and treatment of long-term health conditions that persist after a viral, bacterial, parasitic or fungal infection has cleared.

Closed

Funds pragmatic clinical trials testing tailored nutrition-based care to improve outcomes and quality of life for cancer patients aged 65 and older.

Closed

Funds research and digital interventions that curb the harm excessive or misguided technology use does to the mental health of children and young adults aged 15 to 24.

Closed

Funds research that updates the evidence and methods regulators use to assess medical devices, diagnostics and AI health tools, so safe innovations reach patients faster.

Closed

Funds transnational access to research infrastructure services in one of three areas — industrial biotechnology, radionuclide facilities, or climate prediction.

Closed

Funds transnational access to research infrastructure services for either epidemic-response research or paediatric clinical research, chosen as one area.